Losing weight on Ozempic improves your blood pressure. Fixing your glucose response protects your brain.

When researchers at Brown University began investigating the brains of Alzheimer's patients in the early 2000s, they found something unexpected. The brain tissue showed impaired insulin signalling: cells that had lost the ability to respond to insulin properly, in a pattern similar to what happens in type 2 diabetes. Some researchers now refer to Alzheimer's as type 3 diabetes, though the term remains debated. What isn't debated is the association: people with insulin resistance have a significantly elevated risk of cognitive decline. The brain, which runs almost entirely on glucose, is not insulated from what chronic glucose instability does to the rest of the body.

This matters for how you think about weight loss, and specifically about how you go about it.

Most people who are overweight know, in the abstract, that losing weight is good for their health. Fewer have a clear picture of what that weight is actually doing while it's there, or what different methods of losing it mean for the systems underneath. The number on the scale is a proxy for metabolic health, not a measure of it. Two people can lose the same amount of weight through very different biological processes, and end up in very different physiological states.

What glucose instability is doing in the background

Chronic glucose variability, the repeated cycle of spikes and crashes that follows a diet high in refined carbohydrates and processed food, drives insulin resistance over time. As cells become less responsive to insulin, the pancreas produces more of it to compensate. Elevated insulin promotes fat storage, blocks fat burning, and creates the leptin resistance that makes appetite regulation unreliable. Cortisol rises in response to the glucose crashes, adding visceral fat and further disrupting sleep. The hormonal system begins to spiral in a consistent direction.

Beyond weight, this process has measurable consequences. Chronically elevated blood glucose is independently associated with cardiovascular risk: it damages the endothelial cells lining blood vessels, promotes inflammation, and contributes to arterial stiffening. Even moderately elevated glucose levels, within what was once considered a normal range, predict cardiovascular events. The threshold for harm is lower than most people assume.

The cognitive effects are harder to observe in real time, but the mechanism is the same. The brain accounts for roughly 20% of the body's glucose consumption despite being about 2% of its mass. It depends on a stable supply. Chronic variability, the spike followed by the crash, impairs concentration, memory consolidation, and processing speed in the short term. Over years and decades, the insulin resistance it produces appears to affect the brain's ability to clear amyloid plaques, one of the hallmarks of Alzheimer's pathology. The research here is still developing, but the direction of evidence is consistent enough to take seriously.

What GLP-1 drugs do and don't address

GLP-1 receptor agonists reduce appetite and slow gastric emptying. They produce weight loss, and for many people, measurable improvements in blood glucose and cardiovascular markers in the short term. The cardiovascular benefit data from trials like LEADER and SUSTAIN-6 is real, and worth acknowledging. These are not ineffective drugs.

The gap is what happens at the system level, and what happens after. GLP-1 drugs act on one receptor in a network of interconnected hormonal signals. They reduce caloric intake by suppressing appetite, but they don't restore insulin sensitivity through the mechanisms that make that improvement durable. They don't address cortisol's role in visceral fat accumulation. They don't change how the body handles glucose when food arrives. The weight loss occurs largely because people eat less; the underlying metabolic machinery remains largely as it was.

The muscle loss compounds this. Approximately 40% of the weight lost on GLP-1 drugs is lean muscle mass, not fat. Muscle is not simply a cosmetic concern. It is the body's primary site of glucose disposal: contracting muscle pulls glucose from the bloodstream independently of insulin, which is why resistance exercise improves insulin sensitivity so reliably. Sarcopenia, the age-related loss of muscle mass, is one of the strongest independent predictors of mortality in older adults. It is also associated with accelerated cognitive decline. Losing significant muscle mass during a weight-loss intervention, and then regaining fat when the intervention stops, leaves the metabolic system and the body's long-term resilience in a worse position than before.

What glucose monitoring actually changes

A continuous glucose monitor shows you, in real time, how your body is responding to food, movement, sleep, and stress. The practical effect of that visibility is that behaviour change becomes specific rather than general. You can see which foods spike your glucose and which don't, which means food choices stop being a matter of following generic rules and start being a matter of reading your own data. You can see the effect of a 20-minute walk after lunch on the post-meal curve, and over time the pattern becomes self-reinforcing.

More importantly, the changes this produces work through the hormonal system rather than around it. Flatter glucose responses reduce the insulin load, which over time restores insulin sensitivity. Restored insulin sensitivity allows leptin signalling to function properly, which makes appetite regulation more reliable. Cortisol's chronic elevation decreases as glucose crashes become less frequent. The system begins to recalibrate, and the weight loss that follows is a consequence of that recalibration.

The brain notices too. Members consistently report improvements in concentration and energy stability before they notice significant changes on the scale. The afternoon cognitive slump, driven by the glucose crash that follows a high-carbohydrate lunch, disappears when the curve flattens. This is not a minor quality-of-life improvement. It's a direct signal that the glucose supply to the brain has stabilised, and that the insulin signalling the brain depends on is working more effectively.

The longer view

The question of how to lose weight is inseparable from the question of what you want your health to look like in ten or twenty years. Weight lost while building insulin sensitivity, preserving muscle, and stabilising the hormonal system sets a different biological trajectory from weight lost while those systems remain dysregulated. The first reduces your long-term risk of cardiovascular disease, cognitive decline, and type 2 diabetes. The second reduces a number.

The drugs will likely keep improving. The clinical outcomes data will accumulate. For some people, in some circumstances, they will remain a reasonable option. The case for addressing the underlying system, through the inputs that regulate it, will also keep accumulating. The two approaches are not equivalent in what they leave behind.